Clinical trials: Diabetes, Type II
Diabetes Mellitus, Type 2
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy.
- Trial name
- NCT04090242
- Testing
- BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Becton, Dickinson and Company
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes
Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM
The objective of this protocol is to evaluate the efficacy and cost-effectiveness of 8 sessions of in-home, telephone-delivered, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT)…
- Trial name
- HOME DM-BAT (NCT04203147)
- Testing
- Supportive Therapy (Control), Home DM-BAT
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes Mellitus, Bone Remodeling
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
The purpose of this study is to determine changes in bone turnover markers and calcitonin following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2 diabetes.
- Trial name
- CMBD (NCT01381926)
- Testing
- exenatide, Saline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Depression, Major Depressive Disorder
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT04437485
- Testing
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Indiana University
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02715258
- Testing
- Bexagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Theracos
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Type 2 Diabetes Mellitus With Hypoglycemia, Aging
Prepare for Your Diabetes Care
As adults with type 2 diabetes age, they are increasingly vulnerable to treatment-related hypoglycemia and its related complications (including hospitalization and death).
- Conditions
- Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
- Trial name
- NCT05263310
- Testing
- Prepare for Your Diabetes Care, Usual Care
- Where
- United States
- Volunteers
- 672 people
- Sponsor
- Kaiser Permanente
Osteoporosis, Type 2 Diabetes Mellitus
Effect of Diabetic Medications on Bone Metabolism
Subjects with diabetes and pre-diabetes are said to have increased bone loss when compared to the general population. Pioglitazone a thiazolidinedione, is a Food and Drug Administration (FDA) approved oral anti-diabetic agent for…
- Trial name
- NCT00467285
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2, Covid19
Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
The COVID-19 pandemic has triggered extremely high hospitalization rates where mitigation strategies are urgently necessary to aid vulnerable Hispanic and Latino populations who are experiencing health disparities as well as high…
- Trial name
- NCT04591015
- Testing
- Hospital: DD-CA, Hospital: Usual Care (UC)
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Scripps Whittier Diabetes Institute
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.
- Trial name
- NCT00976495
- Testing
- Dapagliflozin, Hydrochlorothiazide
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on…
- Trial name
- BOOST™ (NCT01059812)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 46 sites in Hong Kong, Japan and 3 more
- Volunteers
- 424 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how much of the drug gets into the blood and how long it takes the body to get rid of it) of single doses of EGT0001474 given to patients…
- Trial name
- NCT00924053
- Testing
- EGT0001474
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Effect of DPP4 Inhibition on Vasoconstriction
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an…
- Trial name
- NCT02639637
- Testing
- Sitagliptin, Neuropeptide Y, Enalaprilat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Type 2
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months.
- Trial name
- NCT01338870
- Testing
- 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 301 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.